How to buy SELLAS Life Sciences Group stock

SELLAS Life Sciences Group, Inc is a biotechnology business based in the US. SELLAS Life Sciences Group shares (SLS) are listed on the NASDAQ and all prices are listed in US Dollars. SELLAS Life Sciences Group employs 7 staff and has a trailing 12-month revenue of around 0.00.

SELLAS Life Sciences Group share price

Use our graph to track the performance of SLS stocks over time.

SELLAS Life Sciences Group shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$1.76 - $12.18
50-day moving average	$8.92
200-day moving average	$6.35
Wall St. target price	$10.00
PE ratio	0.6181
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.35

Buy SELLAS Life Sciences Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy SELLAS Life Sciences Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of SELLAS Life Sciences Group, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is SELLAS Life Sciences Group under- or over-valued?

Valuing SELLAS Life Sciences Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of SELLAS Life Sciences Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

SELLAS Life Sciences Group's P/E ratio

SELLAS Life Sciences Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, SELLAS Life Sciences Group shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

SELLAS Life Sciences Group financials

Revenue TTM	$1.9 million
Gross profit TTM	$1.9 million
Return on assets TTM	-33.88%
Return on equity TTM	-98.41%
Profit margin	0%
Book value	$1.96
Market capitalisation	$118.6 million

TTM: trailing 12 months

Shorting SELLAS Life Sciences Group shares

There are currently 782,265 SELLAS Life Sciences Group shares held short by investors – that's known as SELLAS Life Sciences Group's "short interest". This figure is 8.2% down from 852,109 last month.

There are a few different ways that this level of interest in shorting SELLAS Life Sciences Group shares can be evaluated.

SELLAS Life Sciences Group's "short interest ratio" (SIR)

SELLAS Life Sciences Group's "short interest ratio" (SIR) is the quantity of SELLAS Life Sciences Group shares currently shorted divided by the average quantity of SELLAS Life Sciences Group shares traded daily (recently around 759480.58252427). SELLAS Life Sciences Group's SIR currently stands at 1.03. In other words for every 100,000 SELLAS Life Sciences Group shares traded daily on the market, roughly 1030 shares are currently held short.

However SELLAS Life Sciences Group's short interest can also be evaluated against the total number of SELLAS Life Sciences Group shares, or, against the total number of tradable SELLAS Life Sciences Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SELLAS Life Sciences Group's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 SELLAS Life Sciences Group shares in existence, roughly 50 shares are currently held short) or 0.0519% of the tradable shares (for every 100,000 tradable SELLAS Life Sciences Group shares, roughly 52 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against SELLAS Life Sciences Group.

Find out more about how you can short SELLAS Life Sciences Group stock.

SELLAS Life Sciences Group share dividends

We're not expecting SELLAS Life Sciences Group to pay a dividend over the next 12 months.

Have SELLAS Life Sciences Group's shares ever split?

SELLAS Life Sciences Group's shares were split on a 1:50 basis on 7 November 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SELLAS Life Sciences Group shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for SELLAS Life Sciences Group shares which in turn could have impacted SELLAS Life Sciences Group's share price.

SELLAS Life Sciences Group share price volatility

Over the last 12 months, SELLAS Life Sciences Group's shares have ranged in value from as little as $1.76 up to $12.18. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SELLAS Life Sciences Group's is 1.8708. This would suggest that SELLAS Life Sciences Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

SELLAS Life Sciences Group overview

SELLAS Life Sciences Group, Inc. , a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co. , Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors.

Frequently asked questions

• What percentage of SELLAS Life Sciences Group is owned by insiders or institutions?

  Currently 0.473% of SELLAS Life Sciences Group shares are held by insiders and 10.601% by institutions.

• How many people work for SELLAS Life Sciences Group?

  Latest data suggests 7 work at SELLAS Life Sciences Group.

• When does the fiscal year end for SELLAS Life Sciences Group?

  SELLAS Life Sciences Group's fiscal year ends in December.

• Where is SELLAS Life Sciences Group based?

  SELLAS Life Sciences Group's address is: Times Square Tower, New York, NY, United States, 10036

• What is SELLAS Life Sciences Group's ISIN number?

  SELLAS Life Sciences Group's international securities identification number is: US81642T2096

• What is SELLAS Life Sciences Group's CUSIP number?

  SELLAS Life Sciences Group's Committee on Uniform Securities Identification Procedures number is: 363256108